Sign in

Vun-Sin Lim, PhD

@vslim.bsky.social
158 followers 117 following 51 posts

Managing Editor of the Journal of Thoracic Oncology, the official journal of the IASLC.

PostsRepliesMedia
Vun-Sin Lim, PhD @vslim.bsky.social · 12/09/2026
Wondering about reasons papers get rejected, what papers are good fit for JTO and JTO CRR etc? Have a chat or just listen to the conversations with our Editors-in-Chief on Sunday. @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR #WCLC26
000
Reposted by Vun-Sin Lim, PhD
TOGA @togaanz.bsky.social · 24/05/2026
⏳ Travel grant applications for TOGA ASM 2026 close today. Get your application in before submissions close. 📅 Dates: July 15 - 17 📍 Location: Pullman Melbourne Albert Park Register now > buff.ly/EIdNwaS
001
Reposted by Vun-Sin Lim, PhD
OncoDaily @oncodaily.bsky.social · 20/05/2026
JTO Insights Podcast Episode 3 Highlights Key Takeaways from JTO May Issue - Vun-Sin Lim @vslim.bsky.social oncodaily.com/voices/vun-s... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
oncodaily.com
Vun-Sin Lim: JTO Insights Podcast Episode 3 Highlights Key Takeaways from JTO May Issue - OncoDaily
Vun-Sin Lim: JTO Insights Podcast Episode 3 Highlights Key Takeaways from JTO May Issue / Adam J. Kole, Alex Adjei, Amanda M. Smith, Amber Daniels, Aumkhae
021
Reposted by Vun-Sin Lim, PhD
D. Ross Camidge @drcamidge.bsky.social · 07/05/2026
Grand Rounds at the John Radcliffe Hospital, Oxford. Last time I was here I was a junior doctor from the Oxford University Medical School. This time I could tell a 16 year lung cancer survivor’s story and in the process change hearts and minds about what it means to live with this disease.
181
Reposted by Vun-Sin Lim, PhD
OncoDaily @oncodaily.bsky.social · 20/04/2026
New JTO Podcast “JTO Insights” Is Now Live - Vun-Sin Lim @vslim.bsky.social @jtoonline.bsky.social oncodaily.com/voices/vun-s... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
oncodaily.com
Vun-Sin Lim: New JTO Podcast “JTO Insights” Is Now Live - OncoDaily
Vun-Sin Lim: New JTO Podcast “JTO Insights” Is Now Live / Alex Adjei, cancer, Dinesh Thavendiranathan, JTO, OncoDaily, Oncology, Timothy Burns, Tom John,
011
Reposted by Vun-Sin Lim, PhD
OncoDaily @oncodaily.bsky.social · 22/02/2026
Who Is Training the Next Generation of Journal Editors and Reviewers? - Sompop Bencharit @vslim.bsky.social oncodaily.com/voices/sompo... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
oncodaily.com
Sompop Bencharit: Who Is Training the Next Generation of Journal Editors and Reviewers? - OncoDaily
Sompop Bencharit: Who Is Training the Next Generation of Journal Editors and Reviewers? / cancer, OncoDaily, Oncology, Sompop Bencharit, Vun-Sin Lim
011
Reposted by Vun-Sin Lim, PhD
D. Ross Camidge @drcamidge.bsky.social · 21/01/2026
www.sciencedirect.com/science/arti... Now in press in Journal of Thoracic Oncology - a hypothesis I’ve presented at meetings for a couple of years but never put in writing before.
sciencedirect.com
Hiding in Plain Sight: The Neuro-Protective Benefit of Tyrosine Kinase Inhibition in Non–Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers
162
Vun-Sin Lim, PhD @vslim.bsky.social · 29/12/2025
Thanks @oncodaily.bsky.social for amplifying the authors’ work in JTO! Looking forward to 2026. @jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #lcsm
030
Vun-Sin Lim, PhD @vslim.bsky.social · 03/12/2025
Bring it on! #ScholarlyPublishing #ResearchIntegrity
000
Vun-Sin Lim, PhD @vslim.bsky.social · 05/11/2025
🆕Just published🆕 #LCAM25 Editorial from #JTO Editor-in-Chief Alex Adjei: "Lung Cancer in 2025: Advances in Treatment Continue, but Access Remains Unequal" 🔗 Read the full article here: www.jto.org/article/S155... @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #LCSM
020
Vun-Sin Lim, PhD @vslim.bsky.social · 06/10/2025
Getting ready for #IASLC Asia Conference on Lung Cancer this week! Want to know more about #JTO #JTOCRR publications or Reviewer Workshop? Happy to connect in person. #ACLC25 @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #PeerReview #ScholarlyPublication
021
Vun-Sin Lim, PhD @vslim.bsky.social · 18/09/2025
#WCLC25 It takes a village! Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @iaslc.bsky.social! @jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR
011
Vun-Sin Lim, PhD @vslim.bsky.social · 18/09/2025
#WCLC25 Meet the Editors - Engaging Q&A session between meeting attendees and Editors-in-Chief, Dr Alex Adjei #JTO and Dr Emily Stone #JTOCRR. @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #scholarlypublishing
010
Reposted by Vun-Sin Lim, PhD
D. Ross Camidge @drcamidge.bsky.social · 17/09/2025
kdvr.com/news/health/...
kdvr.com
022
Vun-Sin Lim, PhD @vslim.bsky.social · 10/09/2025
#JTO & #JTOCRR Editorial Reception This annual get-together at #WCLC25 lets editors, top reviewers, the editorial office teams and publisher reconnect in person in a meaningful way in the middle of a very busy conference. @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social
110
Vun-Sin Lim, PhD @vslim.bsky.social · 09/09/2025
#WCLC25 Reviewer Workshop - Here are the next generation of reviewers! It’s heartwarming to know many attendees came here just for this workshop. A few dedicated participants attended online despite unforeseen circumstances. I’m grateful for all of you, faculty and participants. @iaslc.bsky.social
120
Vun-Sin Lim, PhD @vslim.bsky.social · 09/09/2025
#WCLC25 Happening now: IASLC Reviewer Workshop. Alex Adjei - “Top 10 of the do’s and dont’s as a reviewer” @iaslc.bsky.social @jtoonline.bsky.social #JTO #JTOCFR #peerreview
000
Vun-Sin Lim, PhD @vslim.bsky.social · 06/09/2025
#WCLC25 Our #JTO editors got many talents! @drtomjohn.bsky.social @drsanjaypopat.bsky.social @jtoonline.bsky.social @iaslc.bsky.social
020
Reposted by Vun-Sin Lim, PhD
Prof Tom John @drtomjohn.bsky.social · 06/09/2025
Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025
1113
Vun-Sin Lim, PhD @vslim.bsky.social · 06/09/2025
#WCLC25 WS04: Joint IASLC-CSCO-CAALC session happening now in Room 06. Case presentations and discussions with the panelists with global perspectives. @iaslc.bsky.social
000
Vun-Sin Lim, PhD @vslim.bsky.social · 05/09/2025
🆕Special article by Lippman and colleagues in #JTO 📰Press release by UCSD: today.ucsd.edu/story/cancer... @ucsdcancer.bsky.social @iaslc.bsky.social @sciencedirect.bsky.social @elsevierhms.bsky.social @jtoonline.bsky.social #LCSM
today.ucsd.edu
Cancer Breakthrough Sparks New Vaccine
Researchers at UC San Diego and their collaborators have helped answer one of the most difficult questions in oncology: why do some tumors not respond to immunotherapy?
100
Reposted by Vun-Sin Lim, PhD
ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 01/07/2025
Early weight gain as a risk factor for increased maximum weight gain among NSCLC patients on lorlatinib & other ALK tyrosine kinase inhibitors - JTO Clinical and Research Reports. #LCSM #LungCancer www.jtocrr.org/article/S266...
042
Vun-Sin Lim, PhD @vslim.bsky.social · 27/06/2025
✍️June #JTO Editor’s pick 3 of 4: Deuterated Osimertinib 🆓 access: www.jto.org/article/S155... 📎 Also see Deuterated Lorlatinib: www.jto.org/article/S155... 📎 Accompanying editorial: www.jto.org/article/S155... @jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #LCSM
000
Vun-Sin Lim, PhD @vslim.bsky.social · 09/06/2025
🆕 #JTO Review Article from the #IASLC Basic and Translational Science Committee 🆓 access to full texts 🔗 jto.org/article/S155... @jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #lungcancer
000
Vun-Sin Lim, PhD @vslim.bsky.social · 14/05/2025
🆕 #JTO Review Article from IASLC Advanced Radiation Technology subcommittee 🔗 www.jto.org/article/S155... #OpenAccess @iaslc.bsky.social @jtoonline.bsky.social @elsevierconnect.bsky.social
000
Reposted by Vun-Sin Lim, PhD
Dr. Herbert Loong @herbloongmd.bsky.social · 07/05/2025
Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!
042
Vun-Sin Lim, PhD @vslim.bsky.social · 19/04/2025
Full support to Alex Adjei for President-Elect in 2025 #IASLC Board of Directors Election! I have worked with him for 10+ years, inspired by his strong leadership, vision, advocacy, and dedication to patient care, research and publication, and mentoring the next generations. @iaslc.bsky.social
110
Vun-Sin Lim, PhD @vslim.bsky.social · 28/03/2025
@jtoonline.bsky.social @iaslc.bsky.social #JTO #sclc
021
Reposted by Vun-Sin Lim, PhD
The OncoAlert Network 🚨 @oncoalert.bsky.social · 11/03/2025
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer #SCLC : the phase I/II LUPER study www.jto.org/article/S155... The combination demonstrated promising efficacy and a manageable safety profile, particularly for platinum-sensitive patients, warranting further investigation.
021
Reposted by Vun-Sin Lim, PhD
The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/03/2025
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON) www.jto.org/article/S155... These findings suggest that gut microbiota profiling could help optimize treatment strategies for NSCLC.
073
Reposted by Vun-Sin Lim, PhD
Hidehito HORINOUCHI @hhorinouchi.bsky.social · 26/03/2025
⏰NOW OUT‼️ #ELCC25 🔥MARIPOSA🦋: Amivantamab plus lazertinib vs osimertinib in 1L EGFRm advanced NSCLC: Final OS 🎙️Prof. James Yang 🎯OS HR 0.75 (95%CI: 0.61-0.92) 🎯Seems like extending the OS for 1️⃣2️⃣ months ✅NCT04487080 #LCSM #EGFR @oncoalert.bsky.social @myesmo.bsky.social @iaslc.bsky.social
0113
Reposted by Vun-Sin Lim, PhD
Tom Newsom-Davis @tnewsomdavis.bsky.social · 26/03/2025
MARIPOSA final OS analysis ❇️ Significant HR 0.75 ❇️ 9% 3yr benefit ❇️ Projected mOS 4 years ❇️ Longer control of CNS disease ❗️At the cost of toxicity ❗️No data on duration of toxicity ❗️PROM and QoL data important More effective than Osimertinib Most suitable for higher risk pts #ELCC25
0117
Reposted by Vun-Sin Lim, PhD
IASLC @iaslc.bsky.social · 26/03/2025
Congratulations to Keith Kerr, a long-time IASLC member, for receiving the 2025 Heine H Hansen Award at #ELCC2025 👏🏽👏🏽
011
Vun-Sin Lim, PhD @vslim.bsky.social · 23/03/2025
In January 2025, we joined Taiwan Association for the Study of Lung Cancer (TASLC) in running a reviewer workshop in Taipei. 20 selected participants from Taiwan, Malaysia, Thailand, South Korea & Japan attended the workshop. Thanks TASLC for organizing and support! @jtoonline.bsky.social
111
Vun-Sin Lim, PhD @vslim.bsky.social · 22/03/2025
Don’t miss out on this training opportunity! #IASLC Reviewer Workshop applications close on April 1. 🔗 www.iaslc.org/reviewer-wor... @jtoonline.bsky.social @iaslc.bsky.social #JTO #JTOCRR #reviewer
000
Reposted by Vun-Sin Lim, PhD
Hidehito HORINOUCHI @hhorinouchi.bsky.social · 22/03/2025
🌟 @iaslc.bsky.social @jtoonline.bsky.social 🔥Recipients of TOP5️⃣REVIEWERS 1️⃣Dr. Paolo Bironzo 2️⃣Dr. Nicolas Girard 3️⃣Dr. William Evans 4️⃣ @hhorinouchi.bsky.social 5️⃣Dr. Voon Pei Jye 🎉Congratulations🎊 #LCSM @oncoalert.bsky.social
001
Reposted by Vun-Sin Lim, PhD
Hidehito HORINOUCHI @hhorinouchi.bsky.social · 22/03/2025
🔥 @jtoonline.bsky.social 🆙 ✅JCOG2007 (NIPPON): Gut Microbiota in Advanced NSCLC Receiving Chemo-ICI 🎯Differences in microbial diversity and specific bacterial genera were associated with prognosis and serious AEs 👥 Dr. Taiki Hakozaki #LCSM @oncoalert.bsky.social jto.org/article/S155...
jto.org
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
Immunotherapy has transformed treatment for non-small cell lung cancer (NSCLC). However, reliable biomarkers for treatment selection remain scarce. Gut microbiota has emerged as a potential biomarker,...
011
Reposted by Vun-Sin Lim, PhD
Hidehito HORINOUCHI @hhorinouchi.bsky.social · 22/03/2025
🔥 @iaslc.bsky.social @jtoonline.bsky.social 🆙 🥰TOP10 reviewers for 2024 Dr. Jordi Remon Dr. Dipesh Uprety Dr. Molly Siu Ching Li Dr. Kuan-Yu Chen Dr. Junko Tanizaki Dr. Tomer Meirson Dr. Stephanie Saw @hhorinouchi.bsky.social Dr. Misako Nagasaka Dr. Jean-Louis Pujol #LCSM jto.org/article/S155...
jto.org
Journal of Thoracic Oncology
The Editors of the Journal of Thoracic Oncology acknowledge the work of our reviewers for 2024. Many of our reviewers have reviewed multiple manuscripts. We are extremely grateful for their commitment...
011
Reposted by Vun-Sin Lim, PhD
Hidehito HORINOUCHI @hhorinouchi.bsky.social · 22/03/2025
🔥 @jtoonline.bsky.social 🆙 ✅CROWN👑5y: First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC 🎯HR 0.22 (95%CI: 0.13‒0.37), 5-year PFS was 63% (95% CI: 49–74) by lorlatinib 👥 Prof. Yi-long Wu #LCSM @oncoalert.bsky.social jto.org/article/S155...
jto.org
First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study
Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, showed significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patie...
021
Vun-Sin Lim, PhD @vslim.bsky.social · 10/03/2025
Members from Europe, Africa and the Middle East - don’t miss this opportunity to learn how to review manuscripts. ⏰ Deadline to apply: April 1 IASLC Reviewer Workshop: www.iaslc.org/reviewer-wor... @jtoonline.bsky.social @iaslc.bsky.social #reviewer #JTO #JTOCRR
000
Reposted by Vun-Sin Lim, PhD
IASLC @iaslc.bsky.social · 08/03/2025
On this International Women's Day, we celebrate the remarkable women in thoracic oncology who continue to break barriers, lead groundbreaking research, and inspire future generations. Their contributions are vital to shaping the future of lung cancer treatment and advancing equity in medicine.
041
Vun-Sin Lim, PhD @vslim.bsky.social · 07/03/2025
Greatly appreciate the top 5 AND all the reviewers who reviewed for JTO! You can see the full list here: www.jto.org/article/S155... @jtoonline.bsky.social @iaslc.bsky.social #reviewer
010
Reposted by Vun-Sin Lim, PhD
IASLC @iaslc.bsky.social · 06/03/2025
🏆 Congrats to the Top 5 Reviewers for JTO in 2024! 🏆 Your dedication ensures the highest quality research. Thank you to Jordi Remon Masip, Dipesh Uprety, Molly Siu Ching Li, Kuan-Yu Chen, and Junko Tanizaki for your dedication! 👏 🔹 Apply for the 2025 Reviewer Workshop: bit.ly/ReviewerWS
041
Vun-Sin Lim, PhD @vslim.bsky.social · 04/03/2025
2025 CTONG Young mtg in Guangzhou, China - Wonderful opportunity to engage w/ early-career researchers in thoracic oncology from the region in productive discussions. I look fwd to more connections & future collaboration. Honorary Chairs: 吴一龙,周清,钟文昭 Chairs: 张嘉涛,吴芳 @jtoonline.bsky.social
020
Vun-Sin Lim, PhD @vslim.bsky.social · 14/02/2025
🔥 Top 🔟 Most Cited 2024 Articles in JTO 🔥 🧵 @jtoonline.bsky.social @iaslc.bsky.social @elsevierconnect.bsky.social #LCSM
101
Vun-Sin Lim, PhD @vslim.bsky.social · 04/02/2025
#WorldCancerDay - Thanks #Elsevier for including Journal of Thoracic Oncology articles in this special collection ➡️ Read the #JTO collection here: www.sciencedirect.com/journal/jour... @iaslc.bsky.social #lungcancer
linkedin.com
Elsevier Oncology on LinkedIn: #worldcancerday #unitedbyunique
To mark World Cancer Day, we're proud to highlight our special article collection dedicated to innovative research and advancements in cancer treatment…
120
Reposted by Vun-Sin Lim, PhD
Amy C. Moore, PhD @acmoorephd.bsky.social · 19/01/2025
We still have a long way to go to ensure that ALL patients benefit from recent scientific advances in #lungcancer. This study found that overall survival increased by 71% in patients with private insurance compared to only 24% in the uninsured in the US. #LCSM www.jtocrr.org/article/S266...
jtocrr.org
Recent Survival Gains in Stage IV Non-Small Cell Lung Cancer by Sociodemographic Strata
The management of stage IV non-small cell lung cancer (NSCLC) has been transformed by recent innovations. However, access to medical innovations can be variable across sociodemographic groups in the U...
1166
Reposted by Vun-Sin Lim, PhD
Hidehito HORINOUCHI @hhorinouchi.bsky.social · 25/01/2025
🔥 @jtoonline.bsky.social 🆙 ✅Lung cancer screening program quality indicators – review & recommendations 🎯An International Association for the Study of Lung Cancer Delphi process study 👥Dr. Martin C. Tammemägi #LCSM @oncoalert.bsky.social www.jto.org/article/S155...
jto.org
Lung cancer screening program quality indicators – review & recommendations – An International Association for the Study of Lung Cancer Delphi process study
Lung cancer screening (LCS) using low-dose-computed tomography reduces lung cancer mortality in high-risk individuals. Evaluating and monitoring LCS programs are important to ensure and improve qualit...
063
Vun-Sin Lim, PhD @vslim.bsky.social · 25/01/2025
Members from Europe, Africa and the Middle East ➡️ Interested in learning how to review manuscripts? Apply now ➡️ www.iaslc.org/reviewer-wor... #JTO #JTOCRR #peerreview @jtoonline.bsky.social @iaslc.bsky.social #WCLC25
000
Reposted by Vun-Sin Lim, PhD
D. Ross Camidge @drcamidge.bsky.social · 09/01/2025
A story of controversy: During my time as Reviews Editor at the Journal of Thoracic Oncology, Alex Adjei, the editor -in-chief accepted my pitch to have these pro/cons. Inspired by some of the sport seen in fun conference debates. www.sciencedirect.com/science/arti...
sciencedirect.com
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy
1123